Antioxidant Therapeutics in Parkinson's Disease: Current Challenges and Opportunities.
Ana Patricia Duarte-JuradoYareth Gopar-CuevasOdila Saucedo-CardenasMaría de Jesús Loera AriasRoberto Montes de Oca-LunaAracely Garcia-GarciaHumberto Rodríguez-RochaPublished in: Antioxidants (Basel, Switzerland) (2021)
Oxidative stress is considered one of the pathological mechanisms that cause Parkinson's disease (PD), which has led to the investigation of several antioxidants molecules as a potential therapeutic treatment against the disease. Although preclinical studies have demonstrated the efficacy of these compounds to maintain neuronal survival and activity in PD models, these results have not been reflected in clinical trials, antioxidants have not been able to act as disease modifiers in terms of clinical symptoms. Translational medicine currently faces the challenge of redesigning clinical trials to standardize criteria when testing molecules to reduce responses' variability. Herein, we discuss current challenges and opportunities regarding several non-enzymatic antioxidants' therapeutic molecules for PD patients' potential treatment.
Keyphrases
- clinical trial
- oxidative stress
- end stage renal disease
- stem cells
- chronic kidney disease
- newly diagnosed
- dna damage
- ejection fraction
- randomized controlled trial
- ischemia reperfusion injury
- physical activity
- cell therapy
- climate change
- depressive symptoms
- induced apoptosis
- patient reported outcomes
- study protocol
- anti inflammatory
- smoking cessation
- diabetic rats
- heat stress